Iovance Biotherapeutics, Inc. — FY2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018, with unaudited quarterly results, including Q4 2018. The filing was signed February 27, 2019.
Business context
Iovance is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) cell therapies for solid tumors. Its lead candidate, lifileucel, is being studied for metastatic melanoma; LN-145 is under investigation for cervical, head and neck, lung and other cancers. The company had no approved commercial products and generated no revenue.
Financial performance and position
| Metric | FY2018 | FY2017 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $99.8 million | $71.6 million |
| General and administrative expense | $28.4 million | $21.3 million |
| Net loss | $123.6 million | $92.1 million |
| Net loss per share, basic and diluted | $1.27 | $1.41 |
| Net cash used in operating activities | $101.2 million | $78.7 million |
Q4 2018 revenue was $0; net loss attributable to common stockholders was $32.6 million, or $0.27 per share. Q4 2017 net loss was $25.9 million, or $0.36 per share.
FY2018 R&D expense rose 39%, primarily due to higher staffing and consultant costs, increased clinical-trial activity, and additional indications. G&A expense increased 34%, mainly from stock-based compensation and payroll. Net interest income increased to $4.7 million from $0.8 million, reflecting higher cash balances and interest rates. There were no product margins to report.
At December 31, 2018, cash and cash equivalents were $82.2 million and short-term investments were $386.4 million, totaling $468.5 million. Working capital was $461.0 million; total assets were $480.8 million, total liabilities $14.6 million, and stockholders’ equity $466.2 million. No borrowings or debt balance are disclosed in the presented balance sheet. Cash used in investing activities was $386.3 million, primarily reflecting purchases of short-term investments; financing provided $424.3 million, including proceeds from two public offerings. The company reported no off-balance-sheet arrangements.
FY2018 financing included net proceeds of $162.0 million from a January offering and $236.7 million from an October offering. The offerings issued 15.0 million and 25.3 million shares, respectively, materially increasing the share count. The company reported 123.4 million common shares outstanding at year-end.
Material developments and outlook
- In the Phase 2 C-144-01 melanoma study, preliminary Cohort 2 results for 47 patients showed a 38% objective response rate (one complete and 17 partial responses) and median duration of response of 6.4 months at the reported data cutoff. All patients had received anti-PD-1 therapy. Two grade 5 treatment-emergent adverse events were reported; one was possibly related to TIL therapy.
- Preliminary LN-145 results showed a 27% response rate among 15 cervical-cancer patients and a 31% response rate among 13 head-and-neck cancer patients. These were small, interim datasets and may change as enrollment and follow-up continue.
- The FDA granted lifileucel Regenerative Medicine Advanced Therapy designation. Following an end-of-Phase-2 meeting, the FDA acknowledged that a single-arm cohort could potentially support initial registration and that a randomized Phase 3 trial might not be feasible in the intended population. Cohort 4, planned for 75 patients with response assessed by a blinded independent review committee, began enrolling in early 2019.
- Management expected Cohort 4 enrollment to finish in late 2019 or early 2020 and anticipated a BLA submission in the second half of 2020, subject to successful development and regulatory review. The filing also anticipated no product-sale or licensing revenue in 2019, continued operating losses, and increased R&D spending. Management believed available funds would cover anticipated operating expenses for at least 12 months from the filing date.
- The company planned to begin construction of its own U.S. commercial manufacturing facility in 2019, while continuing to rely on contract manufacturers. Its Gen 2 process reduced manufacturing time from 5–6 weeks to 22 days and enabled cryopreservation; scalability, comparability, cost and regulatory validation remained risks.
Risks, contingencies and unusual items
- Iovance had an accumulated deficit of $372.8 million and expected substantial future losses. Its funding outlook depends on clinical progress, regulatory outcomes, manufacturing capacity and potential further financing; future equity issuance could dilute shareholders.
- Clinical results are preliminary and based on small cohorts. Efficacy, durability and safety may differ in later analyses; the filing describes serious adverse events, including two grade 5 events in the melanoma cohort.
- Key risks include FDA acceptance of trial data and the registration strategy, patient enrollment, manufacturing consistency and scale-up, reliance on third parties, competition, intellectual-property protection, and future coverage and reimbursement.
- Outstanding litigation included securities-related derivative actions, a dispute with Solomon Capital, and litigation involving a former executive. The company said some potential losses could not be estimated; it stated management did not believe pending matters would materially adversely affect financial position, results or cash flows. A proposed class-action settlement was preliminarily approved, with its cost expected to be covered by insurance, subject to final approval.
- The company disclosed a 2017 SEC cease-and-desist order related to stock-promotion matters, which it said could make future capital raising more difficult. FY2018 also included a $0.4 million R&D credit following a $1.6 million refund from Karolinska after termination of a clinical-trials agreement.
- Management and the independent auditor reported effective internal control over financial reporting at year-end; the auditor issued unqualified opinions on the financial statements and internal controls.
Most important facts for investors to verify
- Updated Cohort 2 and Cohort 4 efficacy, response durability and safety results, including the status and attribution of serious adverse events.
- Whether Cohort 4 enrolls on the stated timeline and whether the FDA continues to view the single-arm evidence and planned BLA path as adequate.
- Cash burn, cash and investment balances, operating runway, and whether further financing is needed for trials and the planned manufacturing facility.
- Gen 2 manufacturing validation, contract-manufacturer capacity, product comparability and the cost and timing of internal facility construction.
- Developments in the disclosed litigation and any material change to contingent-loss estimates or insurance coverage.